Petros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.82 Insider Own30.08% Shs Outstand20.68M Perf Week-17.57%
Market Cap15.67M Forward P/E- EPS next Y- Insider Trans10.63% Shs Float14.48M Perf Month-38.46%
Income-9.00M PEG- EPS next Q- Inst Own4.70% Short Float0.66% Perf Quarter-49.53%
Sales7.80M P/S2.01 EPS this Y61.10% Inst Trans-18.67% Short Ratio0.06 Perf Half Y-70.02%
Book/sh1.73 P/B0.41 EPS next Y- ROA- Target Price- Perf Year-78.01%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.65 - 5.20 Perf YTD-78.93%
Dividend- P/FCF- EPS past 5Y- ROI-50.80% 52W High-86.51% Beta-
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin79.50% 52W Low8.64% ATR0.13
Employees24 Current Ratio2.60 Sales Q/Q-39.00% Oper. Margin- RSI (14)27.02 Volatility13.09% 10.92%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.09 Prev Close0.68
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.64M Price0.70
Recom- SMA20-28.44% SMA50-39.49% SMA200-62.99% Volume151,070 Change3.01%
May-16-22 05:00PM  
May-03-22 09:23AM  
Apr-27-22 09:25PM  
Apr-26-22 09:15AM  
Apr-19-22 09:15AM  
Apr-01-22 07:00AM  
Mar-03-22 08:00AM  
Feb-01-22 09:15AM  
Jan-24-22 09:15AM  
Jan-18-22 09:20AM  
Jan-06-22 04:30PM  
Jan-05-22 01:38PM  
Dec-28-21 09:15AM  
Dec-22-21 09:10AM  
Dec-08-21 09:15AM  
Dec-02-21 12:00PM  
Nov-30-21 09:00AM  
Nov-15-21 04:30PM  
Nov-11-21 09:15AM  
Nov-08-21 09:15AM  
Nov-03-21 09:16AM  
Oct-21-21 09:25AM  
Oct-19-21 09:25AM  
Oct-14-21 09:00AM  
Sep-23-21 08:30AM  
Sep-10-21 08:30AM  
Aug-17-21 09:25AM  
Aug-16-21 08:30AM  
Aug-12-21 08:00AM  
Aug-11-21 10:39AM  
Jul-27-21 09:25AM  
Jul-13-21 09:15AM  
Jul-12-21 08:15AM  
Jun-02-21 10:12AM  
May-17-21 08:22AM  
May-14-21 08:30AM  
May-07-21 08:00AM  
Mar-18-21 09:00AM  
Feb-18-21 08:00AM  
Feb-04-21 08:30AM  
Jan-19-21 08:00AM  
Dec-08-20 04:15PM  
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHULMAN JOHN DDirectorDec 22Buy3.43145,773500,0015,703,544Jan 03 06:13 AM
SHULMAN JOHN DDirectorNov 29Buy3.00500,0001,500,0005,557,771Nov 30 02:49 PM
SHULMAN JOHN DDirectorOct 18Buy1.721,661,8072,849,9995,057,771Oct 21 08:47 AM